Here, we undertook a cross-sectional study of >64 000 tumor profiles across the 5 most common GI cancer types to establish the prevalence of MTAP-loss, describe genomic differences between MTAP-loss and MTAP-intact tumors, and delineate any intersection with established immunotherapy markers. The gene discussed is MTAP; the disease is neoplasm.